The Unyielding Spirit against Motor Neuron Death:
A Case Report of Exceptionally Slow-Progressing Amyotrophic Lateral Sclerosis Defying Decadal Odds, Complicated by Unresolved Anorexia and Clinical Paradoxes
Dr. Hassan Jazayeri *
*Correspondence to: Dr. Hassan Jazayeri, Neurologue, Tirana- Albania.
Copyright
© 2026 Dr. Hassan Jazayeri, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 07 September 2026
Published: 01 October 2026
DOI: https://doi.org/10.5281/zenodo.23079332
Introduction
In a neurological career spanning over thirty-five years dedicated to clinical practice and teaching, encountering patients with Amyotrophic Lateral Sclerosis (ALS) has always carried a profound sense of inevitability. In standard neurological experience, the trajectory from initial diagnosis to mortality is agonizingly swift, with the vast majority of our patients succumbing to the disease within one to two years, and rarely stretching beyond three. These rapid declines—striking individuals who were physically active just months prior—frequently arrive as a devastating, shocking blow to their families and treating physicians alike.
Yet, medicine occasionally presents profound anomalies that challenge textbook dogmas and redefine our understanding of clinical resilience. This case report shares the extraordinary journey of a patient who has defied statistical expectations, surviving and actively fighting ALS for well over a decade since his initial symptoms in 2012. However, what makes this clinical narrative uniquely compelling—and deeply perplexing—is not merely his survival longevity, but a constellation of baffling clinical paradoxes: severe, unyielding anorexia that has plummeted his weight to 42 kg on a 170 cm frame, well-meaning but misguided therapeutic pressures from colleagues (such as recommendations for 12-hour Riluzole regimens or demanding daily two-hour walks despite complete wheelchair dependency), and a preserved, razor-sharp cognitive and psychological fortitude that stands in stark contrast to his physical wasting.
Case Presentation: The Decadal Battle
The patient, a 66-year-old male, first sought medical attention around 2012 presenting with progressive gait instability and impaired balance during ambulation. A striking clinical feature noted by himself and examining physicians was pronounced volumetric muscle mass wasting spanning both upper and lower extremities. Crucially, despite visible and advanced structural muscle atrophy, serial neurological examinations assessing motor power in his limbs revealed that muscle strength remained entirely normal at that early stage. Initial brain magnetic resonance imaging (MRI) scans were completely normal, ruling out central structural lesions.
Over the ensuing years, the diagnostic pathway navigated through considerable uncertainty. Initial impressions drifted across myopathies and unspecified motor neuron disease (MND) variants. Because of prominent early balance disturbance, preliminary differential diagnoses briefly entertained cerebellar ataxia or atypical parkinsonism, specifically Progressive Supranuclear Palsy (PSP). However, as distal muscle wasting progressed and definitive lower motor neuron signs emerged, these alternative diagnoses were conclusively dismissed. Serial needle electromyography (ENMG) and comprehensive clinical evaluations ultimately established the definitive diagnosis of ALS.
The Paradox of Anorexia and Wasting
Among the most distressing and clinically refractory challenges in this patient's long-term management has been a profound, unyielding anorexia toward all forms of nourishment. Despite extensive investigations by gastroenterology and endocrinology specialists, and numerous consultations with clinical nutritionists, no primary organic gastrointestinal or metabolic pathology has been identified to account for this complete food aversion. Consequently, his weight has plummeted to an alarming 42 kilograms against a height of 170 centimeters.
Some consulting colleagues casually labeled this phenomenon as "anorexia nervosa." However, drawing upon clinical experience with genuine psychiatric eating disorders, applying such a label to this patient is entirely untenable and clinically absurd. This is a man battling a devastating neurodegenerative motor disorder; his refusal or inability to eat stems from complex, poorly understood central autonomic, metabolic, or bulbar-associated dysregulations unique to his slow-progressing phenotype, rather than a psychiatric body-image distortion.
Friction in Management:
Unrealistic Clinical Prescriptions
The patient's longevity has also exposed him to well-intentioned but misguided therapeutic interventions from various practitioners who struggled to contextualize his atypical course. At various points, colleagues insisted that the patient adhere to aggressive therapeutic protocols—such as placing him on rigid 12-hour Riluzole dosing schedules, or bizarrely recommending that he maintain physical conditioning by walking two hours daily—at a time when the patient was entirely wheelchair-bound and lacked even the baseline physical stability to stand. Such disconnects between rigid textbook protocols and the complex reality of advanced, protracted neurodegenerative care highlight the vital need for individualized clinical wisdom.
Reflecting on his medical management, after five continuous years of standard ALS pharmacotherapy yielding zero perceptible clinical stabilization, the patient exercised admirable autonomy. He asked a piercing question: "What problem does taking or not taking these pills solve for me? I prefer to stop." Respecting his rationale, pharmacotherapy was permanently discontinued.
The Triumph of Psychological Resilience Over Physical Decay
What truly elevates this case study is the patient's psychological landscape. In my decades of practice, breaking the news of an ALS diagnosis is met with profound psychological devastation; acceptance is exceedingly rare.
Yet, when I discussed the diagnosis with him frankly in 2020 under sensitive circumstances, his reaction completely defied convention. He listened calmly and remarked: "This has been and will continue to be a part of my life."
From his facial expression and unwavering demeanor, it was evident he had mentally armed himself for a prolonged war. And in practice, that is precisely what happened. Remarkably, despite physical deterioration and profound cachexia, his cognitive faculties and mental health remain exceptionally sharp and intact. He is fully cognizant, emotionally stable, and actively engaged in a psychological war of attrition against his own neurodegeneration.
Comprehensive Clinical Review of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the progressive degeneration of upper motor neurons in the cerebral cortex and lower motor neurons in the brainstem and spinal cord. Amyotrophy reflects muscle denervation and wasting, while lateral sclerosis denotes glial scarring of the corticospinal tracts. Key pathophysiological pillars include glutamate excitotoxicity, mitochondrial dysfunction, protein misfolding (such as TDP-43 aggregation), and neuroinflammation.
ALS is classified into sporadic (90–95%) and familial (5–10%, linked to genes like *C9orf72*, *SOD1*, *TARDBP*, and *FUS*) forms. Global incidence ranges from 1.5 to 2.5 per 100,000 annually, with a slight male preponderance (1.2:1 to 1.5:1) that equalizes past age 70. It affects all races, with a marginally higher frequency in Caucasian populations.
Due to the lack of sufficient facilities and high costs for genotype tests, we could not perform these tests for them, and we were satisfied with the clinical symptoms and duration of the disease. Unfortunately, this patient cannot provide any consistent information from his family in this regard.
Clinical presentations merge upper motor neuron signs (spasticity, hyperreflexia) and lower motor neuron signs (fasciculations, weakness, atrophy). Diagnostic evaluation relies on El Escorial/Awaji criteria, needle electromyography (EMG) demonstrating widespread denervation, and neuroimaging to exclude mimics like cervical spondylotic myelopathy or structural brain lesions.
Standard management involves multidisciplinary supportive care, non-invasive ventilation (BiPAP), nutritional support (PEG), and disease-modifying therapies (Riluzole, Edaravone). While median survival is classically 3 to 5 years (and often under 1 to 2 years in aggressive clinical observation), atypical slow-progressing phenotypes remind clinicians of the biological heterogeneity inherent in motor neuron diseases.
Conclusion
This case report bridges the gap between rigid textbook nosology and the rich, complex tapestry of human clinical reality. A patient surviving over twelve years with ALS while maintaining exceptional cognitive clarity and an unyielding psychological fighting spirit—despite baffling anorexia, severe cachexia (42 kg at 170 cm), and well-meaning but absurd therapeutic prescriptions—offers invaluable lessons for neurologists worldwide. It underscores that behind every statistical survival curve lies a human soul capable of extraordinary resistance.
A Memory of a Man Who Relented Against ALS
Stephen William Hawking (8 January 1942 – 14 March 2018) was an English theoretical physicist, cosmologist and author. He was Director of Research at the Centre for Theoretical Cosmology at the University of Cambridge,[5][6] where he had a career spanning over forty years. His books and lectures have made him a popular figure. He is a Fellow of the Royal Society of Arts and a Fellow of the Pontifical Academy of Sciences, and in 2009 he was awarded the Presidential Medal of Freedom.
Hawking, thirty years old, held the Lucasian Chair in Mathematics from 1979 to 1 October 2009.[7] He is known for his work in cosmology and quantum gravity, particularly on black holes. His book A History of Time, which remained the best-selling book in Britain for a record 237 weeks and was also at the top of the Sunday Times bestseller list, made him famous. His book The Grand Design, published in late 2010, became one of the best-sellers on Amazon within a few days.[8] His surprise sales were surprising.
His book The World in a Nutshell was also a best-selling science book, which he described as a continuation of A History of Time, and which was also one of his favorite books.
Hawking suffered from amyotrophic lateral sclerosis and was unable to move at all; he could neither sit, stand nor walk. He was unable to move his arms or legs or bend or straighten his body, and he was unable to speak.[9] In 2002, Hawking was ranked 25th in a BBC poll of 100 Great Britons.[10] He died on 14 March 2018 at the age of 76 after more than 50 years of living with motor neurone disease.
When I told my patient the story of this exemplary man, he summed up the facts in one sentence: So I can.
References